David Chang, M.D., Ph.D. is the CEO of Allogene Therapeutics, a company he co-founded in June 2018. With a strong background in biomedical sciences, he possesses both an M.D. and a Ph.D., which reflects his deep understanding of the life...
David Chang, M.D., Ph.D. is the CEO of Allogene Therapeutics, a company he co-founded in June 2018. With a strong background in biomedical sciences, he possesses both an M.D. and a Ph.D., which reflects his deep understanding of the life sciences and medicine. Under his leadership, Allogene has made significant strides in developing innovative cancer therapies using CAR T-cell technology. In fact, Dr. Chang was instrumental in achieving key corporate goals, including the initiation of clinical trials and the successful completion of a public offering. His compensation reflects this success; in 2023, he earned over $1.4 million, primarily from his salary and performance bonuses. However, he focuses on driving company performance rather than accumulating wealth through stock options, as he has not reported any vested stock since becoming CEO. David Chang’s previous experience also includes serving as the Chief Medical Officer of Kite Pharma, where he played a key role in developing their CAR T therapies. His strategical perspectives stem from years in the industry, making him a valuable asset in the fast-evolving field of therapeutic development.